Rebel investors lever Bidvest CEO Joffe into chairman's job; Mylan forecasts 16% sales hike for 2014; Endo shareholders OK Paladin buy;

@FiercePharma: Bayer's OTC growth march continues with pickup of China's Dihon. Story | Follow @FiercePharma

@TracyStaton: If you can't get enough of the transition at Novartis: Gist: Shareholders speak at AGM; they like the pay cuts. Story (sub. req.) | Follow @TracyStaton

@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. More | Follow @EricPFierce

@CarlyHFierce: Via FierceBiotech: Regeneron's Schleifer hits the $1B mark, but his biotech is just getting started. Article | Follow @CarlyHFierce

> After thwarting a takeover attempt by Chilean drugmaker CFR Pharmaceuticals, South Africa-based Adcock Ingram's rebel shareholders managed to vault Bidvest CEO Brian Joffe into the drugmaker's chairman's role. Report

> Pittsburgh-based generics maker Mylan ($MYL) predicted its 2014 revenue would rise by as much as 16%, to $7.8 billion to $8.2 billion, with CEO Heather Bresch hinting at a forthcoming buyout. Release

> Malvern, PA-based Endo Health Solutions ($ENDP) shareholders approved its $1.6 billion buyout of the Canadian drugmaker Paladin Labs. Release

> Since the Generic Drug User Fee Act went into effect, the FDA's approval process has grown murky, with less communication between the agency and manufacturers, Momenta Pharmaceuticals ($MNTA) CEO and General Pharmaceutical Association Chairman Craig Wheeler says. Report

> Bedford, MA-based Anika Therapeutics ($ANIK) won FDA approval for its injectable drug Monovisc to treat osteoarthritis in the knee. Report

> The Spanish blood products maker Grifols posted a 35% increase in net profit to €345.6 million, or about $472 million, on revenue of €2.74 billion. Report

Medical Device News

@FierceMedDev: A proposed reform of the tax code would also repeal the 2.3% medical device tax. Naturally, the industry likes. Story | Follow @FierceMedDev

@MarkHFierce: New research suggests that pacers and the like are safe for CT scans, contrary to FDA fears. Item | Follow @MarkHFierce

@MichaelGFierce: From this week's FierceDrugDelivery report: Inner-ear delivery device sends drugs out, draws fluid in. More | Follow @MichaelGFierce

@EmilyWFierce: FDA calls for first major redrawing of food labels since the '90s, putting calorie counts front and center. Article | Follow @EmilyWFierce

> Researchers chide FDA: Pacemaker patients need not fear a CT scan. News

> FDA eyes March for Staar ocular implant review. Story

> Covidien closes its $860M Given Imaging buyout. More

Biotech News

@FierceBiotech: Radius Health looks to catch the IPO wave with $86M pitch. News | Follow @FierceBiotech

@JohnCFierce: Generics manufacturing--the "Wild West." I'm telling you, this is a scandal in the making. Piece via Bloomberg | Follow @JohnCFierce

@DamianFierce: Analyst: Merck's PD-1 promise could heap $5B on 2020 revenue. Story | Follow @DamianFierce

@EmilyMFierce: NIH makes new database on age-related diseases available to researchers. Item | Follow @EmilyMFierce

> Regeneron's Schleifer hits the $1B mark, but his biotech is just getting started. More

> Longtime R&D critic Valeant finds itself with a growing pipeline, and a setback. Story

Pharma Manufacturing News

> Mylan earnings point to reason for Agila deal. Report

> Bayer expands production in China by bagging Dihon. News

> Pfizer gets past shortage of hypothyroid drug Levoxyl. Story

> Critics call for harsher treatment of foreign drugmakers who sell faulty drugs. Article

> Doc goes to jail for lying about foreign-sourced Botox. Story

> AstraZeneca's Delaware campus sold to JPMorgan. Brief

Vaccines News

> H1N1's dominance this flu season makes quadrivalent vaccines' broader protection moot. Story

> Pfizer reports its huge trial of Prevnar has met its primary and secondary goals. News

> CDC is 'not unduly alarmed' by cases of a polio-like illness in California. Story

> Data mining study links seasonal flu vaccine to 24% drop in likelihood of stroke. Research

> MMR vaccine linked to fall in respiratory-related hospitalizations. Investigation

> Taiwan's Adimmune targets June start for mass production of bird flu vaccine. Brief

Editor's Note

> A story in Wednesday's issue of FiercePharma mis-stated the death rate in one of two Pradaxa studies. It was 19.5 per 10,000, not 19.5% per 10,000.

> A story in Tuesday's issue of FiercePharma mistakenly named GlaxoSmithKline as a maker of Testim. GSK formerly co-marketed the drug with Auxilium and never produced it.

And Finally... The FDA proposes new food labels that will highlight added sugars and include more realistic serving sizes. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.